Letters Barriers to access of clinical data

Inadequacy of remote desktop interface for independent reanalysis of data from drug trials

BMJ 2014; 349 doi: http://dx.doi.org/10.1136/bmj.g4353 (Published 09 July 2014) Cite this as: BMJ 2014;349:g4353
  1. Jon N Jureidini, child psychiatrist1,
  2. John M Nardo, clinical assistant professor of psychiatry, Emory University, retired2
  1. 1Paediatric Mental Health Training Unit, University of Adelaide, North Adelaide, SA 5006, Australia
  2. 2Atlanta, GA 30322, USA
  1. Jon.Jureidini{at}Adelaide.edu.au

We write on behalf of a team that has taken on the task of rewriting GlaxoSmithKline’s Study 329 of paroxetine in adolescents under the RIAT (restoring invisible and abandoned trials) project.1 2

GSK granted our RIAT team access to the data from the Paxil Study 329 to do an independent reanalysis, and we’ve now had months of experience working with their “remote desktop” interface as a portal to their information. It is a single windowed multiple document interface, totally self contained, which cannot be accessed by software other than that provided inside the window. Multiple passwords are needed multiple times for access, and some …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe